The Medical Letter on Drugs and Therapeutics
A Plasma-derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new plasma-derived von Willebrand factor/Factor VIII concentrate (Wilate – Octapharma) for treatment of spontaneous and trauma-induced bleeding episodes in patients with von Willebrand disease.

THE DISEASE — Von Willebrand disease (VWD), the most common inherited bleeding disorder, can be detected in up to 1% of the general population, but is symptomatic only in about 0.01%. It is characterized by mucosal bleeding, abnormal platelet adhesion and decreased levels of von Willebrand factor (VWF) and Factor VIII (FVIII). VWF is synthesized in the endothelium and in megakaryocytes and has two roles in normal hemostasis: 1) it mediates platelet activation and adhesion in flowing blood after vascular injury and 2) it stabilizes Factor VIII, the antihemophilic clotting factor. Factor VIII is rapidly degraded in the absence of VWF.

STANDARD TREATMENT — In mild disease, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Plasma-derived Von Willebrand Factor Factor VIII Concentrate (Wilate)
Article code: 1340b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian